Related Experiment Video

Updated: Aug 17, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

[Idiopathic cardiomyopathy]

Haruo Mitani1, Shin-ichi Momomura

  • 1Cardiovascular Center Toranomon Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 9, 2005
PubMed

Insights

Cardiomyopathies are myocardial diseases causing cardiac dysfunction. While treatments exist for heart failure, sudden cardiac death remains a risk, but implantable cardioverter-defibrillators offer protection.

Area of Science:

  • Cardiology
  • Cardiac Electrophysiology

Context:

  • Cardiomyopathies encompass a group of myocardial diseases characterized by cardiac dysfunction.
  • Key types include dilated, hypertrophic, and restrictive cardiomyopathies, each with distinct pathophysiological features.
  • Sudden cardiac death from arrhythmia is a primary concern in cardiomyopathy patients, alongside heart failure.

Purpose:

  • To review the classification and clinical characteristics of cardiomyopathies.
  • To highlight the significant risk of sudden death in cardiomyopathy patients.
  • To discuss current therapeutic strategies and the role of implantable cardioverter-defibrillators.

Summary:

  • Cardiomyopathies are myocardial diseases leading to impaired heart function, classified into dilated, hypertrophic, and restrictive types.
  • While ACE inhibitors and beta-blockers manage heart failure, they do not fully mitigate the high risk of sudden death.
  • Clinical trials indicate that implantable cardioverter-defibrillators (ICDs) are effective in preventing sudden cardiac death in this patient population.

Impact:

  • Provides a concise overview of cardiomyopathy types and their associated risks.
  • Emphasizes the critical role of implantable cardioverter-defibrillators in reducing mortality from sudden cardiac death.
  • Informs clinical decision-making regarding advanced therapies for cardiomyopathy management.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...